Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X by Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, adding:
“Small (n=93) RCT showing OS benefit of Chemoradiotherapy + Immunotherapy vs. observation in resected GB/EHC.
How much benefit due to IO vs. RT component? How would outcomes compare to current SOC of djuvant chemo? RT synergy with IO (since 81% R0 resection)?
Much to explore. Hope for coop trial in this space.”
Quoting Akhil Santhosh‘s post:
“Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
ACCORD: camrelizumab+ cape-RT improves RFS and OS compared to observation in resected GBC and EHCC.”
Title: Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
Journal: JAMA Oncology
Authors: Han Xiao, Jiansong Ji, Shaoqiang Li, Jiaming Lai, Guangyan Wei, Jian Wu, Wei Chen, Wenxuan Xie, Shutong Wang, Liangliang Qiao, Jianfei Tu, Shunli Shen, Zhenwei Peng
More posts featuring Nina Niu Sanford on OncoDaily.